miR-1253对肺腺癌细胞增殖与迁移侵袭能力的影响

目的 探讨微小RNA-1253 （miR-1253）在肺腺癌细胞株中的表达及其对肺腺癌细胞增殖、迁移侵袭能力的影响。方法 采用实时荧光定量PCR（QPCR）检测肺腺癌A549、NCI-H1299、NCI-H157、A973及GLC-82细胞株中的miR-1253表达水平，将miR-1253 mimics和miR-1253 inhibitor分别转染至A973和NCI-H157细胞，以转染阴性对照质粒NC的细胞为阴性对照（NC）组。MTS 实验、克隆形成实验及Transwell 迁移侵袭实验检测不同miR-1253表达对A973和NCI-H157细胞增殖、克隆形成及侵袭转移能力的影响。结果 QPCR检测结果显示，A549、NCI-H1299、NCI-H157、A973及GLC-82细胞中miR-1253相对表达量分别为0.92±0.06、0.06±0.03、1.10±0.26、0.03±0.01、0.45±0.08。A973细胞转染miR-1253 mimics后miR-1253相对表达量显著升高（P＜0.05），NCI-H157细胞转染miR-1253 inhibitor后miR-1253相对表达量显著下降（P＜0.05）。与NC组比较，转染miR-1253 mimics能够显著抑制肺腺癌细胞A973的增殖活性、平板克隆形成能力（166.0±29.3 vs. 371.0±31.4，P=0.001）、迁移 （91.1±32.1 vs. 166.7±33.9，P=0.008）以及侵袭能力 （74.4±20.5 vs. 145.6±28.8，P=0.001）；而miR-1253 inhibitor 能够上调NCI-H157的增殖、平板克隆形成细胞数目（545.0±61.9 vs. 337.0±39.7， P=0.008）、迁移（246.7±36.7 vs. 151.1±32.9，P＜0.001）以及侵袭能力 （231.1±38.8 vs. 137.8±27.3，P=0.001）。结论 miR-1253可以抑制肺腺癌细胞的增殖与侵袭转移，可能作为肺腺癌基因治疗的有效靶点。

Molecular pathologic characteristics and therapeutic strategy for triple negative breast cancer

Triple negative breast cancer is clinically negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptor 2 protein. It is characterized by its unique molecular profile, aggressive behavior and distinct patterns of metastasis. It has become a hotspot in breast cancer research because of its poor prognosis and high incidence of local recurrence and distant metastases. Up to now, we are lack of therapeutic guidelines for this type of breast cancer and some clinical trials are undergoing. This paper summarizes the molecular pathologic profile, current treatment, potential drug targets for triple negative breast cancer.